Pharma Commercial Mock
← All views
Competitive intelligence

CI feed

Conference abstracts + payer decisions interleaved chronologically — the CI team aims to publish a structured briefing within 48 hours of any high-relevance event landing here.

80 items in window · 0 high-relevance

type:allabstractspayer decisionsrelevance:allhighmediumlow
  1. Payermedium (61%)health plan commercialtier changed
    2025-06-02
    UnitedHealthcare moved ZENVARA from preferred to non-preferred tier.
    UnitedHealthcareUS-nationallives: 11,785,892effective: 2025-08-01
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  2. Payermedium (66%)pbm commercialadded
    2025-06-03
    Express Scripts added ZENVARA to NSCLC formulary tier 3 with PA.
    Express ScriptsUS-nationallives: 82,839,689effective: 2025-06-10
    Decision targets ZENVARA's direct competitor in NSCLC.
  3. Payermedium (50%)va national formularyadded
    2025-06-03
    VA Pharmacy Benefits Management added ZENVARA to NSCLC formulary tier 3 with PA.
    VA Pharmacy Benefits ManagementUS-nationallives: 8,888,996effective: 2025-06-03
    Decision affects adjacent indication; potential read-through to ZENVARA.
  4. Payermedium (46%)hta intlvalue assessment final
    2025-06-04
    HAS (France) published final value assessment for ZENVARA in NSCLC.
    HAS (France)UKlives: 17,329,018effective: 2025-06-04
    Class-wide implications relevant to all assets with this mechanism.
  5. Payermedium (66%)pbm commercialadded
    2025-06-13
    OptumRx added ZENVARA to NSCLC formulary tier 3 with PA.
    OptumRxUS-nationallives: 75,035,003effective: 2025-07-10
    Decision targets ZENVARA's direct competitor in NSCLC.
  6. Payermedium (61%)va national formularyadded
    2025-06-15
    VA Pharmacy Benefits Management added ZENVARA to NSCLC formulary tier 3 with PA.
    VA Pharmacy Benefits ManagementUS-nationallives: 9,301,763effective: 2025-08-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  7. Payermedium (64%)health plan commercialrestriction removed
    2025-06-15
    Kaiser Permanente removed step-therapy requirement on ZENVARA.
    Kaiser PermanenteUS-nationallives: 20,415,265effective: 2025-06-15
    Decision targets ZENVARA's direct competitor in NSCLC.
  8. Payermedium (63%)state medicaid pdladded
    2025-06-17
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:MIlives: 10,468,409effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  9. Payermedium (68%)state medicaid pdlpdl preferred status changed
    2025-06-17
    New York DOH updated PDL preferred status for ZENVARA.
    New York DOHUS-state:CAlives: 11,869,624effective: 2025-06-17
    Decision targets ZENVARA's direct competitor in NSCLC.
  10. Payermedium (54%)hospital pt committeeadded
    2025-06-21
    Ascension added ZENVARA to NSCLC formulary tier 3 with PA.
    AscensionUS-nationallives: 357,466effective: 2025-07-23
    Decision concerns ZENVARA's reference product.
  11. Payermedium (45%)state medicaid pdlremoved
    2025-06-22
    Texas HHSC removed ZENVARA from formulary effective 2025-07-30.
    Texas HHSCUS-state:MIlives: 2,389,692effective: 2025-07-30
    Decision concerns ZENVARA's reference product.
  12. Payermedium (50%)health plan commercialrestriction added
    2025-06-23
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 19,401,818effective: 2025-06-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA
  13. Payermedium (62%)pbm commercialrestriction added
    2025-06-25
    OptumRx added prior-authorization requirement to ZENVARA.
    OptumRxUS-nationallives: 63,888,214effective: 2025-06-25
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  14. Payermedium (49%)va national formularyrestriction added
    2025-06-28
    VA Pharmacy Benefits Management added prior-authorization requirement to ZENVARA.
    VA Pharmacy Benefits ManagementUS-nationallives: 8,621,008effective: 2025-08-23
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA
  15. Payermedium (66%)pbm medicare pdpadded
    2025-06-28
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 11,381,927effective: 2025-08-10
    Decision targets ZENVARA's direct competitor in NSCLC.
  16. Payermedium (50%)cms ncdcoverage decision
    2025-06-29
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,239,095effective: 2025-06-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
  17. Payermedium (60%)pbm medicare pdprestriction added
    2025-07-01
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 4,960,790effective: 2025-08-16
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  18. Payermedium (52%)state medicaid pdlremoved
    2025-07-01
    Florida AHCA removed ZENVARA from formulary effective 2025-08-26.
    Florida AHCAUS-state:GAlives: 2,782,010effective: 2025-08-26
    Class-wide implications relevant to all assets with this mechanism.
  19. Payermedium (55%)state medicaid pdladded
    2025-07-02
    Pennsylvania DHS added ZENVARA to NSCLC formulary tier 3 with PA.
    Pennsylvania DHSUS-state:TXlives: 2,308,782effective: 2025-07-03
    Decision concerns ZENVARA's reference product.
  20. Payermedium (53%)cms ncdcoverage decision
    2025-07-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 61,878,624effective: 2025-07-03
    Decision affects adjacent indication; potential read-through to ZENVARA.
  21. Payermedium (66%)cms lcdcoverage decision
    2025-07-04
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J15lives: 10,103,223effective: 2025-07-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  22. Payermedium (51%)pbm medicare pdpadded
    2025-07-07
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 11,904,986effective: 2025-07-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
  23. Payermedium (53%)state medicaid pdlpdl preferred status changed
    2025-07-08
    California DHCS updated PDL preferred status for ZENVARA.
    California DHCSUS-state:FLlives: 4,286,117effective: 2025-07-08
    Decision affects adjacent indication; potential read-through to ZENVARA.
  24. Payermedium (47%)va national formularyadded
    2025-07-13
    VA Pharmacy Benefits Management added ZENVARA to NSCLC formulary tier 3 with PA.
    VA Pharmacy Benefits ManagementUS-nationallives: 9,479,567effective: 2025-09-08
    Decision affects adjacent indication; potential read-through to ZENVARA.
  25. Payermedium (51%)pbm commercialadded
    2025-07-13
    OptumRx added ZENVARA to NSCLC formulary tier 3 with PA.
    OptumRxUS-nationallives: 75,891,098effective: 2025-07-28
    Class-wide implications relevant to all assets with this mechanism.
  26. Payermedium (43%)hospital pt committeerestriction added
    2025-07-17
    Ascension added prior-authorization requirement to ZENVARA.
    AscensionUS-nationallives: 928,899effective: 2025-08-20
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: ST
  27. Payermedium (40%)state medicaid pdladded
    2025-07-19
    Florida AHCA added ZENVARA to NSCLC formulary tier 3 with PA.
    Florida AHCAUS-state:OHlives: 5,290,386effective: 2025-08-04
    Decision concerns ZENVARA's reference product.
  28. Payermedium (63%)pbm commercialstep therapy imposed
    2025-07-23
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 84,078,547effective: 2025-08-21
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,PA
  29. Payermedium (52%)state medicaid pdlpdl preferred status changed
    2025-07-25
    Texas HHSC updated PDL preferred status for ZENVARA.
    Texas HHSCUS-state:ILlives: 7,751,414effective: 2025-07-25
    Class-wide implications relevant to all assets with this mechanism.
  30. Payermedium (42%)cms lcdcoverage decision
    2025-07-26
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JNlives: 5,601,401effective: 2025-07-26
    Class-wide implications relevant to all assets with this mechanism.
  31. Payermedium (67%)cms lcdcoverage decision
    2025-07-26
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JLlives: 7,606,429effective: 2025-07-26
    Decision targets ZENVARA's direct competitor in NSCLC.
  32. Payermedium (66%)hospital pt committeerestriction added
    2025-07-26
    CommonSpirit Health added prior-authorization requirement to ZENVARA.
    CommonSpirit HealthUS-nationallives: 1,601,801effective: 2025-09-03
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA,LA
  33. Payermedium (69%)hospital pt committeeremoved
    2025-07-29
    Ascension removed ZENVARA from formulary effective 2025-09-16.
    AscensionUS-nationallives: 859,723effective: 2025-09-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  34. Payermedium (64%)pbm commercialexcluded
    2025-07-31
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-09-04.
    OptumRxUS-nationallives: 103,851,148effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  35. Payermedium (61%)cms ncdcoverage decision
    2025-08-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 62,634,101effective: 2025-08-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  36. Payermedium (62%)state medicaid pdlremoved
    2025-08-03
    Pennsylvania DHS removed ZENVARA from formulary effective 2025-08-27.
    Pennsylvania DHSUS-state:NYlives: 6,077,599effective: 2025-08-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  37. Payermedium (55%)health plan commercialrestriction added
    2025-08-05
    BCBS Federal Employee Program added prior-authorization requirement to ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 11,062,358effective: 2025-09-16
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: PA
  38. Payermedium (69%)hta intlvalue assessment final
    2025-08-05
    G-BA (Germany) published final value assessment for ZENVARA in NSCLC.
    G-BA (Germany)EU-DElives: 12,945,419effective: 2025-08-05
    Decision targets ZENVARA's direct competitor in NSCLC.
  39. Payermedium (60%)pbm commercialtier changed
    2025-08-06
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 61,556,077effective: 2025-09-22
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 3
  40. Payermedium (69%)pbm medicare pdpadded
    2025-08-06
    Express Scripts Medicare added ZENVARA to NSCLC formulary tier 3 with PA.
    Express Scripts MedicareUS-nationallives: 7,948,955effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  41. Payermedium (65%)dod tricareremoved
    2025-08-07
    DoD TRICARE removed ZENVARA from formulary effective 2025-09-28.
    DoD TRICAREUS-nationallives: 9,874,504effective: 2025-09-28
    Decision targets ZENVARA's direct competitor in NSCLC.
  42. Payermedium (45%)health plan commercialrestriction removed
    2025-08-12
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 22,614,523effective: 2025-08-12
    Decision affects adjacent indication; potential read-through to ZENVARA.
  43. Payermedium (47%)pbm commercialstep therapy imposed
    2025-08-13
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 96,094,770effective: 2025-09-13
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA,ST
  44. Payermedium (51%)pbm commercialtier changed
    2025-08-13
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 70,846,268effective: 2025-08-13
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 5
  45. Payermedium (48%)state medicaid pdlremoved
    2025-08-14
    Texas HHSC removed ZENVARA from formulary effective 2025-09-15.
    Texas HHSCUS-state:TXlives: 12,088,622effective: 2025-09-15
    Decision affects adjacent indication; potential read-through to ZENVARA.
  46. Payermedium (42%)hospital pt committeeremoved
    2025-08-15
    CommonSpirit Health removed ZENVARA from formulary effective 2025-08-23.
    CommonSpirit HealthUS-nationallives: 256,998effective: 2025-08-23
    Decision affects adjacent indication; potential read-through to ZENVARA.
  47. Payermedium (46%)health plan commercialrestriction removed
    2025-08-15
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 14,431,683effective: 2025-08-15
    Class-wide implications relevant to all assets with this mechanism.
  48. Payermedium (61%)icervalue assessment draft
    2025-08-19
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 53,976,744effective: 2025-08-19
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: C-value_for_money: lowprice_benchmark_usd: 146627
  49. Payermedium (44%)icerprice benchmark
    2025-08-22
    ICER updated value-based price benchmark for ZENVARA.
    ICERUS-nationallives: 54,075,372effective: 2025-08-22
    Decision affects adjacent indication; potential read-through to ZENVARA.
    price_benchmark_usd: 135092value_for_money: intermediate
  50. Payermedium (67%)hta intlvalue assessment final
    2025-08-27
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)CAlives: 38,000,992effective: 2025-08-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  51. Payermedium (46%)health plan commercialtier changed
    2025-09-04
    BCBS Federal Employee Program moved ZENVARA from preferred to non-preferred tier.
    BCBS Federal Employee ProgramUS-nationallives: 19,419,551effective: 2025-09-12
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 4
  52. Payermedium (52%)cms lcdcoverage decision
    2025-09-08
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J5lives: 7,979,811effective: 2025-09-08
    Class-wide implications relevant to all assets with this mechanism.
  53. Payermedium (67%)cms lcdcoverage decision
    2025-09-09
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J8lives: 6,613,739effective: 2025-09-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  54. Payermedium (64%)health plan commercialrestriction removed
    2025-09-13
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 20,297,150effective: 2025-09-13
    Decision targets ZENVARA's direct competitor in NSCLC.
  55. Payermedium (52%)cms ncdcoverage decision
    2025-09-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 63,864,823effective: 2025-09-14
    Decision concerns ZENVARA's reference product.
  56. Payermedium (67%)cms lcdcoverage decision
    2025-09-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JMlives: 8,155,597effective: 2025-09-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  57. Payermedium (69%)state medicaid pdlremoved
    2025-09-17
    New York DOH removed ZENVARA from formulary effective 2025-10-27.
    New York DOHUS-state:PAlives: 9,199,503effective: 2025-10-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  58. Payermedium (65%)va national formularyrestriction added
    2025-09-17
    VA Pharmacy Benefits Management added prior-authorization requirement to ZENVARA.
    VA Pharmacy Benefits ManagementUS-nationallives: 9,246,996effective: 2025-09-28
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  59. Payermedium (60%)health plan commercialrestriction removed
    2025-09-19
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 14,342,981effective: 2025-09-19
    Decision targets ZENVARA's direct competitor in NSCLC.
  60. Payermedium (52%)icervalue assessment final
    2025-09-23
    ICER published final value assessment for ZENVARA in NSCLC.
    ICERUS-nationallives: 79,890,217effective: 2025-09-23
    Decision affects adjacent indication; potential read-through to ZENVARA.
    rating: Dvalue_for_money: intermediateprice_benchmark_usd: 152130
  61. Payermedium (63%)pbm medicare pdptier changed
    2025-09-26
    OptumRx Medicare moved ZENVARA from preferred to non-preferred tier.
    OptumRx MedicareUS-nationallives: 9,419,390effective: 2025-10-23
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 5
  62. Payermedium (46%)health plan commercialrestriction added
    2025-09-26
    BCBS Federal Employee Program added prior-authorization requirement to ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 15,413,374effective: 2025-11-10
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: LA
  63. Payermedium (67%)pbm medicare pdpadded
    2025-10-01
    CVS Caremark SilverScript added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS Caremark SilverScriptUS-nationallives: 7,614,520effective: 2025-10-15
    Decision targets ZENVARA's direct competitor in NSCLC.
  64. Payermedium (61%)pbm commercialexcluded
    2025-10-02
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-11-23.
    OptumRxUS-nationallives: 91,369,413effective: 2025-11-23
    Decision targets ZENVARA's direct competitor in NSCLC.
  65. Payermedium (50%)health plan commercialrestriction removed
    2025-10-03
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 20,204,776effective: 2025-10-03
    Decision affects adjacent indication; potential read-through to ZENVARA.
  66. Payermedium (49%)state medicaid pdlremoved
    2025-10-03
    Florida AHCA removed ZENVARA from formulary effective 2025-10-20.
    Florida AHCAUS-state:GAlives: 2,789,638effective: 2025-10-20
    Decision concerns ZENVARA's reference product.
  67. Payermedium (66%)pbm commercialexcluded
    2025-10-04
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-11-19.
    OptumRxUS-nationallives: 62,405,297effective: 2025-11-19
    Decision targets ZENVARA's direct competitor in NSCLC.
  68. Payermedium (64%)pbm medicare pdptier changed
    2025-10-08
    OptumRx Medicare moved ZENVARA from preferred to non-preferred tier.
    OptumRx MedicareUS-nationallives: 3,568,654effective: 2025-11-29
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 4
  69. Congressmediumembargo lifts in 1d
    Jun 1, 2026, 9:15 PM
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-16
    Median OS 19.6 months. HR 0.75 (95% CI 0.64–0.86). Grade ≥3 AEs consistent with prior reports.
    Tecentriq () · RocheNSCLCIMpower-16 · NCT45181053Trials in Progress Poster Session
    OS
    19.6 months
    HR 0.75 (0.64-0.86)
    PFS
    10.1 months
    HR 0.74 (0.64-0.88)
    ORR
    51.2 percent
  70. Congressmediumembargo lifts in 1d
    Jun 1, 2026, 10:00 PM
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-560
    Median OS 18 months. HR 0.83 (95% CI 0.71–0.95). No new safety signals identified.
    Keytruda () · MerckTNBCKEYNOTE-560 · NCT60389648Poster Discussion Session
    OS
    18 months
    HR 0.83 (0.71-0.95)
    PFS
    11 months
    HR 0.81 (0.74-0.94)
    ORR
    41.2 percent
  71. Congressmediumembargo lifts in 2d
    Jun 2, 2026, 3:30 PM
    CheckMate-957: Opdivo (nivolumab) neoadjuvant in HCC
    Median OS 19.2 months. HR 0.62 (95% CI 0.51–0.73). No new safety signals identified.
    Opdivo () · Bristol-Myers SquibbHCCCheckMate-957 · NCT64844073Education Session
    OS
    19.2 months
    HR 0.62 (0.51-0.73)
    PFS
    8.6 months
    HR 0.64 (0.54-0.74)
    ORR
    32.5 percent
  72. Congressmediumembargo lifts in 2d
    Jun 2, 2026, 4:45 PM
    Real-world effectiveness of Opdivo vs standard of care in RCC
    Median OS 51.4 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.
    Opdivo () · Bristol-Myers SquibbRCCCheckMate-903 · NCT76925924Oral Abstract Session
    OS
    51.4 months
    HR 0.83 (0.74-0.92)
    PFS
    23.3 months
    HR 0.83 (0.75-0.92)
    ORR
    55.7 percent
  73. Congressmediumembargo lifts in 2d
    Jun 2, 2026, 9:30 PM
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    Median OS 24 months. HR 0.81 (95% CI 0.69–0.93). No new safety signals identified.
    Keytruda () · MerckTNBCKEYNOTE-968 · NCT24586311Poster Session
    OS
    24 months
    HR 0.81 (0.69-0.93)
    PFS
    7.2 months
    HR 0.79 (0.7-0.97)
    ORR
    40.4 percent
  74. Congressmediumembargo lifts in 3d
    Jun 3, 2026, 3:00 PM
    DESTINY-Breast-179: Enhertu (trastuzumab deruxtecan) adjuvant in gastric
    Median OS 18.8 months. HR 0.88 (95% CI 0.74–0.99). No new safety signals identified.
    Enhertu () · Daiichi SankyogastricDESTINY-Breast-179 · NCT43607208Publication Only
    OS
    18.8 months
    HR 0.88 (0.74-0.99)
    PFS
    7.9 months
    HR 0.89 (0.72-0.97)
    ORR
    49.7 percent
  75. Congressmediumembargo lifts in 3d
    Jun 3, 2026, 4:45 PM
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-845
    Median OS 29.2 months. HR 0.58 (95% CI 0.48–0.68). Grade ≥3 AEs consistent with prior reports.
    Opdivo () · Bristol-Myers SquibbNSCLCCheckMate-845 · NCT53991773Late-Breaking Oral Abstract Session
    OS
    29.2 months
    HR 0.58 (0.48-0.68)
    PFS
    10.6 months
    HR 0.55 (0.44-0.65)
    ORR
    47.7 percent
  76. Congressmediumembargo lifts in 4d
    Jun 4, 2026, 8:15 PM
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    Median OS 38 months. HR 0.62 (95% CI 0.48–0.76). No new safety signals identified.
    Lynparza () · AstraZenecaHR+ breast cancerOlympiA-594 · NCT43314812Poster Discussion Session
    OS
    38 months
    HR 0.62 (0.48-0.76)
    PFS
    23.1 months
    HR 0.61 (0.47-0.76)
    ORR
    63.1 percent
  77. Congressmediumembargo lifts in 4d
    Jun 4, 2026, 9:00 PM
    Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-860
    Median OS 20.7 months. HR 0.88 (95% CI 0.76–0.99). No new safety signals identified.
    Tecentriq () · RocheNSCLCIMpower-860 · NCT14419528Education Session
    OS
    20.7 months
    HR 0.88 (0.76-0.99)
    PFS
    11.4 months
    HR 0.85 (0.76-0.96)
    ORR
    40.1 percent
  78. Congressmediumembargo lifts in 4d
    Jun 4, 2026, 9:30 PM
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-252
    Median OS 33.1 months. HR 0.68 (95% CI 0.6–0.76). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-252 · NCT49268597Poster Session
    OS
    33.1 months
    HR 0.68 (0.6-0.76)
    PFS
    21.5 months
    HR 0.65 (0.6-0.78)
    ORR
    74.8 percent
  79. Congressmediumembargo lifts in 5d
    Jun 5, 2026, 3:15 PM
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-569 study)
    Median OS 16.4 months. HR 0.85 (95% CI 0.75–0.95). No new safety signals identified.
    Imfinzi () · AstraZenecaNSCLCPACIFIC-569 · NCT82451698Education Session
    OS
    16.4 months
    HR 0.85 (0.75-0.95)
    PFS
    9.1 months
    HR 0.87 (0.78-0.99)
    ORR
    50.7 percent
  80. Congressmediumembargo lifts in 5d
    Jun 5, 2026, 7:15 PM
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-421
    Median OS 12.5 months. HR 0.8 (95% CI 0.72–0.88). Grade ≥3 AEs consistent with prior reports.
    Trodelvy () · Gileadurothelial carcinomaASCENT-421 · NCT53826507Poster Session
    OS
    12.5 months
    HR 0.8 (0.72-0.88)
    PFS
    8.7 months
    HR 0.8 (0.69-0.84)
    ORR
    31.6 percent